NO954399L - 8-substituerte xanthiner som selektive adenosinreseptormidler - Google Patents
8-substituerte xanthiner som selektive adenosinreseptormidlerInfo
- Publication number
- NO954399L NO954399L NO954399A NO954399A NO954399L NO 954399 L NO954399 L NO 954399L NO 954399 A NO954399 A NO 954399A NO 954399 A NO954399 A NO 954399A NO 954399 L NO954399 L NO 954399L
- Authority
- NO
- Norway
- Prior art keywords
- adenosine receptor
- adenosine
- iii
- lower alkyl
- receptor activity
- Prior art date
Links
- 102000009346 Adenosine receptors Human genes 0.000 title abstract 4
- 108050000203 Adenosine receptors Proteins 0.000 title abstract 4
- -1 8-substituted xanthines Chemical class 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000001766 physiological effect Effects 0.000 abstract 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- YMIXWSVDZOGUBN-UHFFFAOYSA-N amino hypofluorite Chemical compound NOF YMIXWSVDZOGUBN-UHFFFAOYSA-N 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Xantinderivater med generell struktur (I) i O (D innbefattende (R)- og (S)-enantiomerer og racemiske blandinger derav, og far- masøytisk akseptable salter derav, hvori RJ og R2 hver uavhengig er (Cj- C4)-lavere alkyl eller (C2-C4)-lavere alkenyl, Z er (II) (ID eller (III) (III) eller (IV) (IV) CHj)n hvori R3 er hydrogen, (C^-Gj) -lavere alkyl, nitro, amino, hydroksy, fluor, brom eller klor, R< er (Ct-C4)-lavere alkyl, og n er l eller 2, som virker selektivt ved adenosinreseptorer og som virker generelt som adenosinantagon- ister, er beskrevet. Fra in vi tro studier er det kjent at spesifikke fysiologiske effekter kan skjelnes som et resultat av denne selektivitet, og at adenosinreseptoraktivitet in vltro korrelerer med adenosinreseptoraktivi- jtet in vivo. Farmasøytiske preparater ;av angjeldende forbindelser kan frem- stilles på basis av den selektive bin- | dingsaktivitet av de her beskrevne for- i bindelser som vil øke visse fysiolog- 1 iske effekter samtidig som andre vil minimeres, slik som nedsettelse av blodtrykk uten nedsettelse av hjertehastighet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5852393A | 1993-05-06 | 1993-05-06 | |
| PCT/US1994/004038 WO1994026744A1 (en) | 1993-05-06 | 1994-04-13 | 8-substituted xanthines as selective adenosine receptor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO954399D0 NO954399D0 (no) | 1995-11-03 |
| NO954399L true NO954399L (no) | 1996-01-08 |
Family
ID=22017346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO954399A NO954399L (no) | 1993-05-06 | 1995-11-03 | 8-substituerte xanthiner som selektive adenosinreseptormidler |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5734052A (no) |
| EP (1) | EP0697020A1 (no) |
| JP (1) | JPH08509977A (no) |
| CN (1) | CN1043473C (no) |
| AU (1) | AU676323B2 (no) |
| CA (1) | CA2159989C (no) |
| FI (1) | FI955257A0 (no) |
| HU (1) | HUT72327A (no) |
| IL (1) | IL109521A (no) |
| MX (1) | MX9403382A (no) |
| NO (1) | NO954399L (no) |
| NZ (1) | NZ265790A (no) |
| WO (1) | WO1994026744A1 (no) |
| ZA (1) | ZA943015B (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025362A (en) * | 1998-08-31 | 2000-02-15 | Fukunaga; Atsuo F. | Uses of xanthine compounds |
| US6258794B1 (en) | 1999-12-14 | 2001-07-10 | The Mclean Hospital Corporation | Treatment of mental conditions including depression |
| US8871751B2 (en) * | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435916A (en) * | 1972-05-11 | 1976-05-19 | Beecham Group Ltd | Pharmaceutical weight-reducing compositions |
| US4772607A (en) * | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
-
1994
- 1994-04-13 CA CA002159989A patent/CA2159989C/en not_active Expired - Fee Related
- 1994-04-13 JP JP6525431A patent/JPH08509977A/ja active Pending
- 1994-04-13 HU HU9503154A patent/HUT72327A/hu unknown
- 1994-04-13 US US08/553,253 patent/US5734052A/en not_active Expired - Fee Related
- 1994-04-13 CN CN94192005A patent/CN1043473C/zh not_active Expired - Fee Related
- 1994-04-13 EP EP94914770A patent/EP0697020A1/en not_active Withdrawn
- 1994-04-13 NZ NZ265790A patent/NZ265790A/en unknown
- 1994-04-13 AU AU67032/94A patent/AU676323B2/en not_active Ceased
- 1994-04-13 WO PCT/US1994/004038 patent/WO1994026744A1/en not_active Ceased
- 1994-05-02 ZA ZA943015A patent/ZA943015B/xx unknown
- 1994-05-03 IL IL10952194A patent/IL109521A/xx not_active IP Right Cessation
- 1994-05-06 MX MX9403382A patent/MX9403382A/es not_active IP Right Cessation
-
1995
- 1995-11-02 FI FI955257A patent/FI955257A0/fi unknown
- 1995-11-03 NO NO954399A patent/NO954399L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU676323B2 (en) | 1997-03-06 |
| IL109521A0 (en) | 1994-08-26 |
| CN1122599A (zh) | 1996-05-15 |
| JPH08509977A (ja) | 1996-10-22 |
| US5734052A (en) | 1998-03-31 |
| CA2159989C (en) | 1994-11-24 |
| FI955257A7 (fi) | 1995-11-02 |
| MX9403382A (es) | 1995-01-31 |
| NO954399D0 (no) | 1995-11-03 |
| ZA943015B (en) | 1995-01-30 |
| AU6703294A (en) | 1994-12-12 |
| HU9503154D0 (en) | 1996-01-29 |
| NZ265790A (en) | 1996-10-28 |
| HUT72327A (en) | 1996-04-29 |
| FI955257A0 (fi) | 1995-11-02 |
| EP0697020A1 (en) | 1996-02-21 |
| IL109521A (en) | 1999-09-22 |
| WO1994026744A1 (en) | 1994-11-24 |
| CN1043473C (zh) | 1999-05-26 |
| CA2159989A1 (en) | 1994-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vogelgesang et al. | Stereoselective first‐pass metabolism of highly cleared drugs: studies of the bioavailability of L‐and D‐verapamil examined with a stable isotope technique. | |
| US5117830A (en) | Method of determining viability of tissue | |
| ES2157224T3 (es) | Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1). | |
| US6995148B2 (en) | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy | |
| US3879554A (en) | Use of 1,6-dimethyl-8-{62 -(5-bromonicotinoyloxymethyl)-10 {60 -methoxyergoline in treating cerebral and peripheral metabolic vascular disorders | |
| ES2098510T3 (es) | Antagonista de galanina. | |
| NO954399L (no) | 8-substituerte xanthiner som selektive adenosinreseptormidler | |
| FI901549A0 (fi) | Menetelmä terapeuttisesti käyttökelpoisten fenyylialkyleeniaminosubstituoitujen puriini- ja pyratsolo/3,4-d/pyrimidiinijohdannaisten valmistamiseksi | |
| CS156882A2 (en) | Process for preparing derivatives of benzmide | |
| CA2038747A1 (en) | Selective adenosine receptor agents | |
| ES8801280A1 (es) | Procedimiento para la obtencion de benzo-(pirano y tiopirano)-piridinas | |
| EA200001192A1 (ru) | Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона | |
| Lippmann et al. | Effects of the administration of epsilon amino caproic acid on catecholamine and serotonin levels in the rat and dog | |
| UA41329C2 (uk) | Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії | |
| FR2618435B1 (fr) | Derives de benzimidazole, leur preparation et leur application en therapeutique | |
| ES2174220T3 (es) | Uso de derivados de 4-fenil-3,6-dihidro-2h-piridilo como agentes bloqueantes de subtipos de receptores nmda. | |
| Scrutinio et al. | Objective evaluation of gallopamil in patients with chronic stable angina. Exercise testing, Holter monitoring, cross-sectional echocardiography and plasma levels | |
| EP0390111A3 (en) | Selective adenosine receptor compounds | |
| Desager et al. | Relative acute cardiovascular toxicity induced by maprotiline, mianserin and nomifensine in conscious rabbits | |
| AR005613A1 (es) | Empleo de los derivados de la tetrahidroisoquinolina | |
| NO303875B1 (no) | 2-substituerte adenosiner med A-2-reseptoraffinitet | |
| RU92016587A (ru) | Новые производные бензопирана, активатор калиевого канала |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |